Link Technologies Ltd Release: The One-Stop Guide to Oligo Modification

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BELLSHILL, SCOTLAND, 3 September 2013: Link Technologies Ltd, a specialist oligonucleotide reagent manufacturer, has dedicated a section of its new, freely available 2013/14 Product Guide to ‘Modification Strategies in Oligonucleotide Synthesis’. Increasingly, modified oligos are playing an important role across a broad range of life science and clinical-based research groups and, for example, show significant promise as agents to optimise drug delivery. In the new Product Guide, Link Technologies has compiled a comprehensive resource for - scientists working with modified oligonucleotides, including educational references, detailed product information, established protocols and application notes, for assured oligo synthesis and use. This go-to guide for oligonucleotide chemistry can be downloaded for free from www.linktech.co.uk

ISO 9001:2008 certified, Link Technologies offers an extensive range of modified phosphoramidites, enabling scientists to take advantage of numerous techniques and a diverse range of applications. This includes brancher phosphoramidites to facilitate the generation of branched oligos as a tool for gene expression analysis or gene correction, and hydrophobic group modifiers (cholesterol, tocopherol and palmitate) which have had recent success in aiding the cellular delivery of oligonucleotides. Application-orientated for easy use, the 2013/14 Product Guide directs scientists to the most suitable products for purpose and, with the associated tried-and-tested protocols, allows users to have confidence in the performance of their modified oligos.

To download the Link Technologies’ 2013/14 Product Guide, or to request your free copy, please visit the company website at www.linktech.co.uk

About Link Technologies Ltd

Link Technologies Ltd is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification, all to the ISO 9001:2008 quality certification. The company’s main markets are university and commercial research departments, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector. Link has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners.

For further information see: www.linktech.co.uk.

Help employers find you! Check out all the jobs and post your resume.

Back to news